Scotiabank analyst George Farmer initiated coverage of Biomea Fusion with an Outperform rating and $41 price target. The analyst rolled out coverage of the companies working on menin inhibition with two Outperforms and one Sector Perform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
- Biomea Fusion announces preliminary data from Phase I COVALENT-101 trial
- Unusually active option classes on open June 27th
- Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
- Jefferies downgrades Biomea Fusion, says data ‘seem to raise more questions’